Equities

MaxCyte Inc

MaxCyte Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)270.00
  • Today's Change-5.00 / -1.82%
  • Shares traded74.65k
  • 1 Year change+0.93%
  • Beta--
Data delayed at least 20 minutes, as of Nov 13 2024 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments168227255
Total Receivables, Net5.78146.88
Total Inventory128.585.20
Prepaid expenses3.902.783.31
Other current assets, total------
Total current assets190252270
Property, plant & equipment, net353413
Goodwill, net------
Intangibles, net------
Long term investments43----
Note receivable - long term------
Other long term assets0.390.810.32
Total assets268287284
LIABILITIES
Accounts payable------
Accrued expenses128.187.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total5.076.716.75
Total current liabilities181516
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total18175.61
Total liabilities363321
SHAREHOLDERS EQUITY
Common stock1.041.021.01
Additional paid-in capital407391376
Retained earnings (accumulated deficit)(176)(138)(114)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity232254263
Total liabilities & shareholders' equity268287284
Total common shares outstanding104102101
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.